Oakland K, et al. - The experts undertook this study to compare outcomes of patients receiving anti-platelets, anti-coagulants, or direct oral anti-coagulants (DOACs) who developed lower gastrointestinal bleeding (LGIB). In addition, they analyzed the effects of withholding these drugs on their course of bleeding. Antiplatelet drugs were correlated with an increased risk of re-bleeding in patients with LGIB. However, this was not true for warfarin or DOACs. During admission, withholding anti-platelets did not lead to a reduction in re-bleeding.